Tech Company Financing Transactions
Forty Seven Funding Round
Forty Seven, based in Menlo Park, secured $75 million in investment from Wellington Management Company, Clarus and GV.
Transaction Overview
Company Name
Announced On
10/18/2017
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
Wellington Management Company (Lead Investor)
Clarus (Dennis Henner)
GV (Blake Byers)
Sutter Hill Ventures (Jeff Bird)
Proceeds Purpose
The funds will be used to support continued development of Hu5F9-G4, an antibody against CD47, which takes the brakes off macrophages in a similar way as checkpoint inhibitors take the brakes off T-cells.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1490 O'Brien Dr. A
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
With a passion for pioneering breakthrough solutions, Forty Seven Inc. is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark McCamish
Chief Financial Officer
Ann Rhoads
Chief Medical Officer
Chris Takimoto
Founder
Mark Chao
VP - Bus. Development
Craig Gibbs
VP - Manufacturing
Qinghai Zhao
VP - Operations
Kyle Elrod
VP - R & D
Jens-Peter Volkmer
Browse more venture capital transactions:
Prev: 10/18/2017: UpStack venture capital transaction
Next: 10/19/2017: Vemba venture capital transaction
Share this article
News on VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs